Yahoo
NSE - Delayed Quote INR

NATCO Pharma Limited (NATCOPHARM.NS)

782.15 -5.40 (-0.69%)
At close: October 30 at 3:30:01 PM GMT+5:30
Chart Range Bar
Loading chart for NATCOPHARM.NS
  • Previous Close 787.55
  • Open 792.05
  • Bid --
  • Ask --
  • Day's Range 779.50 - 800.90
  • 52 Week Range 773.60 - 1,226.80
  • Volume 321,547
  • Avg. Volume 466,727
  • Market Cap (intraday) 153.433B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 12.34
  • EPS (TTM) 63.37
  • Earnings Date Nov 13, 2026
  • Forward Dividend & Yield 5.95 (0.76%)
  • Ex-Dividend Date Aug 20, 2026
  • 1y Target Est 1,004.44

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

www.natcopharma.co.in

4,433

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

NATCOPHARM.NS
13.10%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

NATCOPHARM.NS
5.65%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

NATCOPHARM.NS
0.15%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

NATCOPHARM.NS
2.08%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 7.35B
Earnings 2.06B
Profit Margin 28.09%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
5B
10B
25.0%
30.0%
35.0%

Analyst Insights

View More

Analyst Price Targets

712.00
1,004.44 Average
782.15 Current
1,180.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    32.84%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    34.85B

  • Net Income Avi to Common (ttm)

    11.44B

  • Diluted EPS (ttm)

    63.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.29B

  • Total Debt/Equity (mrq)

    7.74%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: